IncuBio S.A. to attract financing for early stage proof-of-concept clinical trials of new biotech and pharmaceutical products. Photo: Chokniti Khongchum
A new joint venture company, IncuBio S.A., has been established in the Mariel Special Development Zone to attract venture capital for the funding of early stage proof-of-concept clinical trials of new biotech and pharmaceutical products.
IncuBIO holds an exclusive license for the development and commercialization of biotech products, including NeuroEPO, one of the most promising pharmaceuticals from the Center of Molecular Immunology (CIM).
By financing the clinical trials prospective investors will acquire shares in the company and increase product market value.
Cuba’s CIMAB S.A. and Neuronic Mexicana S.A. de C.V. of Mexico are the new partners in the joint venture.
CIMAB S.A., was founded in 1992. It is a division of the Center for Molecular Immunology (CIM). The company develops and markets monoclonal antibodies and other recombinant proteins for the diagnosis and treatment of cancer, cardiology and other autoimmune diseases.
Neuronic Mexicana S.A. was founded in 1996. The company focuses on neuroscience. It is also involved in the development and marketing of biopharmaceutical products and medical equipment.
IncuBIO is now a shareholder in five joint venture companies located in Cuba, China, Thailand, and Singapore.
From our staff writers and editors.
Cuba has confirmed the 41st edition of the Havana International Fair (FIHAV 2025) will take…
WestJet CEO Alexis von Hoensbroech met Wednesday with Cuban President Miguel Díaz-Canel in Havana, a high-level meeting…
Cuba is ramping up efforts to address energy shortages through the expansion of photovoltaic solar…
Renowned Cuban pianist Marcos Madrigal has been named Chevalier de l’Ordre des Arts et des Lettres by…
Russia will provide funding of $1 billion dollars for investment projects in Cuba, according to…
Cuba’s Foreign Affairs Minister Bruno Rodríguez Parrilla met with China's Foreign Minister, Wang Yi, on…